BACKGROUND: Pancreatic cancer (PC) is a highly lethal malignancy, even if surgical resection is possible (median survival: < 30 months). The prognosis of borderline resectable pancreatic cancer (BR-PC) is even worse. There is no clear consensus on the optimal treatment strategy, including pre/postoperative therapy, for BR-PC. We report a patient with BR-PC who achieved clinical partial response with neoadjuvant chemoradiation therapy (NACRT) and underwent curative resection, resulting in pathological complete response (pCR). CASE PRESENTATION: A 71-year-old man with jaundice and liver dysfunction was referred to our department because of a 48-mm hypo-vascular mass in the pancreatic head with obstruction of the pancreatic and bile ducts and infiltration of superior mesenteric vein and portal vein. The lesion was identified as atypical cells which suggested adenocarcinoma by biopsy, and he was administered NACRT: gemcitabine and nab-paclitaxel, following S-1 and intensity modulated radiation therapy. After reduction in the tumor size (clinical partial response), pancreaticoduodenectomy was performed, and pCR achieved. Postoperative adjuvant chemotherapy with S-1 was initially administered and the patient is currently alive with no recurrence as of 2 years after surgery. CONCLUSIONS: NACRT is a potentially useful treatment for BR-PC that may lead to pCR and help improve prognosis.
BACKGROUND: Pancreatic cancer (PC) is a highly lethal malignancy, even if surgical resection is possible (median survival: < 30 months). The prognosis of borderline resectable pancreatic cancer (BR-PC) is even worse. There is no clear consensus on the optimal treatment strategy, including pre/postoperative therapy, for BR-PC. We report a patient with BR-PC who achieved clinical partial response with neoadjuvant chemoradiation therapy (NACRT) and underwent curative resection, resulting in pathological complete response (pCR). CASE PRESENTATION: A 71-year-old man with jaundice and liver dysfunction was referred to our department because of a 48-mm hypo-vascular mass in the pancreatic head with obstruction of the pancreatic and bile ducts and infiltration of superior mesenteric vein and portal vein. The lesion was identified as atypical cells which suggested adenocarcinoma by biopsy, and he was administered NACRT: gemcitabine and nab-paclitaxel, following S-1 and intensity modulated radiation therapy. After reduction in the tumor size (clinical partial response), pancreaticoduodenectomy was performed, and pCR achieved. Postoperative adjuvant chemotherapy with S-1 was initially administered and the patient is currently alive with no recurrence as of 2 years after surgery. CONCLUSIONS: NACRT is a potentially useful treatment for BR-PC that may lead to pCR and help improve prognosis.
Authors: Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven Journal: J Clin Oncol Date: 2020-02-27 Impact factor: 44.544
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Stephen W Behrman; Al B Benson; Dana B Cardin; E Gabriela Chiorean; Vincent Chung; Brian Czito; Marco Del Chiaro; Mary Dillhoff; Timothy R Donahue; Efrat Dotan; Cristina R Ferrone; Christos Fountzilas; Jeffrey Hardacre; William G Hawkins; Kelsey Klute; Andrew H Ko; John W Kunstman; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Amol K Narang; Jorge Obando; Patricio M Polanco; Sushanth Reddy; Marsha Reyngold; Courtney Scaife; Jeanne Shen; Charles Vollmer; Robert A Wolff; Brian M Wolpin; Beth Lynn; Giby V George Journal: J Natl Compr Canc Netw Date: 2021-04-01 Impact factor: 11.908
Authors: Ashton A Connor; Robert E Denroche; Gun Ho Jang; Mathieu Lemire; Amy Zhang; Michelle Chan-Seng-Yue; Gavin Wilson; Robert C Grant; Daniele Merico; Ilinca Lungu; John M S Bartlett; Dianne Chadwick; Sheng-Ben Liang; Jenna Eagles; Faridah Mbabaali; Jessica K Miller; Paul Krzyzanowski; Heather Armstrong; Xuemei Luo; Lars G T Jorgensen; Joan M Romero; Prashant Bavi; Sandra E Fischer; Stefano Serra; Sara Hafezi-Bakhtiari; Derin Caglar; Michael H A Roehrl; Sean Cleary; Michael A Hollingsworth; Gloria M Petersen; Sarah Thayer; Calvin H L Law; Sulaiman Nanji; Talia Golan; Alyssa L Smith; Ayelet Borgida; Anna Dodd; David Hedley; Bradly G Wouters; Grainne M O'Kane; Julie M Wilson; George Zogopoulos; Faiyaz Notta; Jennifer J Knox; Steven Gallinger Journal: Cancer Cell Date: 2019-01-24 Impact factor: 31.743
Authors: Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook Journal: JAMA Surg Date: 2016-08-17 Impact factor: 14.766
Authors: Jin He; Alex B Blair; Vincent P Groot; Ammar A Javed; Richard A Burkhart; Georgios Gemenetzis; Ralph H Hruban; Kevin M Waters; Justin Poling; Lei Zheng; Daniel Laheru; Joseph M Herman; Martin A Makary; Matthew J Weiss; John L Cameron; Christopher L Wolfgang Journal: Ann Surg Date: 2018-07 Impact factor: 13.787